DESCRIPTION:
Cabazitaxel is a microtubule inhibitor. Cabazitaxel binds to tubulin and promotes its assembly into microtubules while simultaneously inhibiting disassembly. This leads to the stabilization of microtubules, which results in the inhibition of mitotic and interphase cellular functions. JEVTANA (cabazitaxel) is an antineoplastic agent belonging to the taxane class. It is prepared by semi-synthesis with a precursor extracted from yew needles.

INDICATION(S):
JEVTANA® is a microtubule inhibitor indicated in combination with prednisone for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.

The individual dosage of JEVTANA is based on calculation of the Body Surface Area (BSA) and is 25 mg/m2 administered as a one-hour intravenous infusion every three weeks in combination with oral prednisone 10 mg administered daily throughout JEVTANA treatment.

REASONS FOR PA:
- Cost
- Potential for misuse
- Toxicity

CRITERIA for APPROVAL:
1. Patient is diagnosed with metastatic (hormone refractory) prostate cancer?
2. Patient had a trial of a docetaxel-containing regimen?
3. Dosing will be 25 mg/mm2 every three weeks in combination with Oral Prednisone 10mg administered daily throughout JEVTANA treatment.

REASONS for DENIAL of BENEFIT:
1. Patient has a known history of sensitivity to medication or to any component of the product or Polysorbate 80
2. Patients has a neutrophil count of ≤ 1,500/mm3
3. Patient does not meet above criteria

RENEWAL CRITERIA:
Review of past demonstrates a reduced frequency of clinical exacerbations and improved health-related quality of life

BENEFIT APPROVAL:
Initial approval for a period of 3 months. Renewal approval period: 3 months

References:
Jentana® Product Information, sanofi-aventis U.S. LLC Bridgewater, NJ 08807 June 2010